Transmembrane proteins (TPs), also referred to as ‘integral membrane proteins’, make up between 70 % and 80 % of the total ...

Bulk harvest release testing for adventitious viruses is an integral part of biosafety for manufacturing biopharma products. Finding a testing strategy that works for diverse biologics modalities ...

Taste, pain, or response to stress -- nearly all essential functions in the human body are regulated by molecular switches called G protein-coupled receptors (GPCRs). Researchers have uncovered ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

Targeting challenging proteins:9 AI is opening new therapeutic options for challenging proteins like GPCRs and ion channels, which are vital drug targets involved in multiple diseases but ...

CXCR4 is highly selective for CXCL12 and activates heterotrimeric G proteins. In contrast, ACKR3 is quite promiscuous and does not couple to G proteins, but like most G protein-coupled receptors ...

Pfizer announced it will end development of its oral GLP-1 weight loss pill danuglipron, citing risk of liver injury. The move gives Novo Nordisk and Eli Lilly a bit more time of having the only ...

Solu Therapeutics, a company developing a new type of antibody drug, unveiled $41 million in financing on Wednesday for clinical testing of a therapy with the potential to bring a safer and more ...

A new study shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.

Exicure has been granted a patent for “GPCR Heteromer Inhibitors and Uses Thereof,” protecting its innovative approach to cancer treatment that targets GPCRx and CXCR4. The company’s Phase 2 clinical ...